Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 528
Filter
2.
Clin Microbiol Infect ; 22(11): 948.e1-948.e7, 2016 Nov.
Article in English | MEDLINE | ID: mdl-27515395

ABSTRACT

Staphylococcus aureus bacteraemia (SAB) is a frequent and deadly disease. Given the lack of a randomized trial, optimal first-line antibiotic treatment is still debated. Our aim was to identify prognostic factors in SAB patients and to analyse the impact of first-line antibiotics. The VIRSTA prospective cohort study was conducted in eight tertiary care centres in France. Consecutive incident adults in whom a blood culture drawn in participating centres grew S. aureus between April 2009 and October 2011 were prospectively followed for 12 weeks. Factors associated with 12-week case-fatality were identified by multivariate logistic regression. We enrolled 2091 patients and analysed survival in 1972 (median age 67.8 years, interquartile range 55.5-78.9; females 692/1972, 35.1%). SAB was nosocomial or healthcare-related in 1372/1972 (69.6%) of cases and the primary focus was unknown in 414/1972 (21.0%) of cases. Week 12 case-fatality rate was 671/1972 (34.0%). The main independent prognostic factors on multivariate analysis were age (adjusted OR by 10-year increment 1.56; 95% CI 1.44-1.69), septic shock (OR 5.11; 95% CI 3.84-6.80), metastatic cancer (OR 4.28; 95% CI 2.88-6.38), and unknown primary focus (OR 2.62; 95% CI 2.02-3.41). In the 1538 patients with methicillin-sensitive S. aureus (MSSA) bacteraemia, first-line empiric antistaphylococcal penicillins (OR 0.40; 95% CI 0.17-0.95) and vancomycin (OR 0.37; 95% CI 0.17-0.83), alone or combined with an aminoglycoside, were associated with better outcome compared with other antibiotics. There are few modifiable prognostic factors for SAB. Initiating empiric antibiotics with antistaphylococcal penicillins or vancomycin may be associated with better outcome in MSSA bacteraemia.


Subject(s)
Bacteremia/drug therapy , Bacteremia/mortality , Penicillins/administration & dosage , Staphylococcal Infections/drug therapy , Staphylococcal Infections/mortality , Vancomycin/administration & dosage , Aged , Bacteremia/epidemiology , Cross Infection/epidemiology , Cross Infection/mortality , Female , France/epidemiology , Humans , Male , Middle Aged , Penicillins/therapeutic use , Prognosis , Prospective Studies , Staphylococcal Infections/epidemiology , Staphylococcus aureus , Survival Analysis , Tertiary Care Centers , Vancomycin/therapeutic use
3.
Rev Med Interne ; 37(2): 84-90, 2016 Feb.
Article in French | MEDLINE | ID: mdl-26302696

ABSTRACT

PURPOSE: The diagnostic value of selective anorexia is debated. Some authors have suggested an association between meat aversion and cancer, but most do not use it as a diagnostic tool. We aimed to characterize anorexia of different diseases to search for an association between selective aversions and diagnostic groups. METHODS: All the patients admitted to three departments of a teaching hospital were included consecutively for 22months if they had more than 10 % weight loss in less than one year. Patients were excluded if history taking was not reliable, or if they suffered from anorexia nervosa. We compiled diagnoses at discharge and validated them six months later. We used logistic regression to identify independent factors associated with selective anorexia. RESULTS: Inclusion criteria were met in 106patients (female 44 %, median age 65years). Most frequent diagnoses were: cancer (36 %), infection (35 %), digestive diseases (19 %), non organic diseases (21 %). Recent selective anorexia was found in 46 % of the cases. It was significantly associated with female gender (P=0.002), marginally with young age (P=0.069) and long duration of weight loss (P=0.079). Opioid use at admission was negatively associated with selective anorexia (P=0.001). No specific diagnostic category was found to be associated. CONCLUSION: Selective anorexia does not appear to be a useful symptom to investigate pathological weight loss. It behaves more like a non-specific reactivation by current disease of earlier latent personal food aversions.


Subject(s)
Anorexia/etiology , Symptom Assessment , Taste , Weight Loss , Aged , Aged, 80 and over , Anorexia/classification , Female , Humans , Male , Middle Aged , Prospective Studies , Surveys and Questionnaires
4.
Curr Eye Res ; 18(5): 342-8, 1999 May.
Article in English | MEDLINE | ID: mdl-10372995

ABSTRACT

PURPOSE: Platelet activating factor is a lipid which has been strongly implicated in anterior uveitis. In order to investigate further the role of platelet activating factor in intraocular inflammation, we have characterized the histological changes associated with the intravitreal injection of platelet activating factor, PAF analogs, or lyso-PAF in laboratory rabbits and rats. METHODS: Initial studies utilized a PAF analog (rac 1-0-octadecyl 2-0-ethyl glycero phosphoryl choline or ethoxy PAF), because this compound is relatively resistant to degradation by hydrolase, the major degradative enzyme for PAF. Doses ranging from 1 ug to 5 mg and time points from 6 hours to 7 days after injection were studied. RESULTS: In either rats or rabbits, 100 ug of ethoxy PAF consistently induced a marked uveitis with the predominance of inflammation focused in the retina and choroid. Retinitis was also induced in rabbits by either 1 mg PAF injected intravitreally or a similar dose of the PAF precursor/metabolite, lyso PAF. Retinal inflammation was not induced by an inactive lipid, 1,1-0,0-dihexadecyl-rac-glycero-3-phosphocholine, although this compound resulted in mild vitreous inflammation. The histological changes induced by PAF could be readily distinguished from the predominantly anterior inflammation induced by intravitreal injections of substances such an interleukin-1 or endotoxin. CONCLUSIONS: Recent studies indicating that PAF antagonists inhibit a variety of retinal toxicities and our own observations suggest that PAF could be a major mediator of retinal inflammation.


Subject(s)
Platelet Activating Factor , Retinitis/chemically induced , Vitreous Body/physiology , Animals , Female , Inflammation Mediators/administration & dosage , Injections , Male , Platelet Activating Factor/administration & dosage , Platelet Activating Factor/analogs & derivatives , Rabbits , Rats , Rats, Sprague-Dawley , Retinitis/pathology , Time Factors
5.
Eur Urol ; 33(3): 340-7, 1998.
Article in English | MEDLINE | ID: mdl-9555564

ABSTRACT

OBJECTIVE: To assess the effect of the lipidosterolic extract of Serenoa repens (LSESr) on in vitro cell proliferation in biopsies of human prostate MATERIAL AND METHODS: Cell proliferation was assessed by incorporation of [3H]thymidine followed by historadiography. RESULTS: Basic fibroblast growth factor (b-FGF) induced a considerable increase in human prostate cell proliferation (from +100 to +250%); the glandular epithelium was mainly affected, minimal labeling being recorded in the other regions of the prostate. Similar results were observed with epidermal growth factor (EGF), although the increase in cell proliferation was not recorded in some cases. Lovastatin, an inhibitor of hydroxymethylglutaryl coenzyme A, antagonized both the basal proliferation and the growth factor-stimulated proliferation of human prostate epithelium (EGF, mean inhibition approximately 80-95%; b-FGF, mean inhibition approximately 40-90%). Geraniol, a precursor of both farnesyl pyrophosphate and geranylgeranyl pyrophosphate, and farnesol, the precursor of farnesyl pyrophosphate, increased cell proliferation only in some prostate specimens, this effect being antagonized by lovastatin. LSESr did not affect basal prostate cell proliferation, with the exception of two prostate specimens in which a significant inhibition of basal proliferation was observed with the highest concentration of LSESr (30 micrograms/ ml). In contrast, LSESr inhibited b-FGF-induced proliferation of human prostate cell cultures; this effect was significant for the highest concentration of LSESr (30 micrograms/ml). In some prostate samples, a similar inhibition was also noted with lower concentrations. Unsaturated fatty acids (UFA), in the range 1-30 ng/ml), did not affect the basal prostate cell proliferation, only a slight increase in cell proliferation was noted in 1 prostate specimen. UFA (1, 10 or 30 micrograms/ml) markedly inhibited the b-FGF-induced cell proliferation down to the basal value. Lupenone, hexacosanol and the unsaponified fraction of LSESr markedly inhibited the b-FGF-induced cell proliferation, whereas a minimal effect on basal cell proliferation was noted. CONCLUSIONS: Despite the large variability in the response of the prostate samples to b-FGF, these results indicate that LSESr and its components affect the proliferative response of prostate cells to b-FGF more than their basal proliferation.


Subject(s)
Androgen Antagonists/pharmacology , Fibroblast Growth Factor 2/pharmacology , Plant Extracts/pharmacology , Prostate/drug effects , Acyclic Monoterpenes , Cell Division/drug effects , Cells, Cultured , Epidermal Growth Factor/pharmacology , Farnesol/pharmacology , Humans , Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology , Lovastatin/pharmacology , Male , Plant Extracts/chemistry , Prostate/pathology , Prostatic Hyperplasia/pathology , Serenoa , Terpenes/pharmacology
6.
Prostaglandins Leukot Essent Fatty Acids ; 57(3): 299-304, 1997 Sep.
Article in English | MEDLINE | ID: mdl-9384520

ABSTRACT

Although the lipidic extract of Serenoa repens (LESSr, Permixon, Sereprostat) is widely used in patients suffering from benign prostatic hypertrophy (BPH), its mechanism of action is not fully elucidated. It has been demonstrated that infiltration of the prostate by inflammatory cells is one of the aetiologic factors involved in the development of BPH. These inflammatory cell types, such as polymorphonuclear neutrophils (PMNs), produce chemotactic mediators and contribute to the development of the disease. Among the chemotactic factors generated by inflammatory cell types, the derivatives of arachidonic acid have been extensively studied. For instance, leukotriene (LT) B4 is one of the most potent chemotactic factors for PMNs and also exhibits a wide range of biological activities. In order to investigate the potential action of LESSr on arachidonate metabolism, and particularly on the synthesis of LTB4, the effect of this extract on the in vitro synthesis of LT by human PMNs stimulated with the calcium ionophore A23187 was investigated. LESSr significantly inhibits the production of 5-lipoxygenase metabolites (5-HETE, 20-COOH LTB4, LTB4 and 20-OH LTB4) at concentrations as low as 5 microg/ml. Such an effect of LESSr was also observed in the presence of exogenous arachidonic acid (20 microg/ml) and when f-MLP was used as the agonist, suggesting that inhibition of LTB4 production by the extract was unrelated to phospholipase A2 blockade and independent of the stimulating agent. The capability of LESSr to antagonize 5-lipoxygenase metabolites production may contribute, at least partly, to the understanding of its therapeutic activity on the inflammatory component of BPH.


Subject(s)
Calcimycin/pharmacology , Ionophores/pharmacology , Leukotriene B4/biosynthesis , Neutrophils/metabolism , Plant Extracts/pharmacology , Arachidonate 5-Lipoxygenase/metabolism , Cell Survival , Humans , Male , N-Formylmethionine Leucyl-Phenylalanine/pharmacology , Neutrophils/drug effects , Prostatic Hyperplasia/drug therapy , Serenoa
7.
Gastroenterology ; 111(4): 1081-91, 1996 Oct.
Article in English | MEDLINE | ID: mdl-8831604

ABSTRACT

BACKGROUND & AIMS: Pancreatitis is characterized by inflammation and death of acinar cells. Death can occur by either necrosis or apoptosis. The initial injury may cause expression of cytokines that mediate activation and infiltration of neutrophils. The aim of this study was to assess the effect of neutrophils and platelet-activating factor (PAF) in cell death responses. METHODS: The effects of neutrophil depletion with antineutrophil serum (ANS) and a PAF antagonist (BN52021) were measured in the cerulein model of pancreatitis. Rats received a 6-hour intravenous infusion of cerulein either alone or after treatment with ANS, BN52021, or both. RESULTS: Cerulein-induced pancreatitis was characterized by neutrophilic infiltration, vacuolization of acinar cells, and foci of necrosis. Treatment with ANS and BN52021 prevented the inflammatory response caused by cerulein and decreased the cell damage. Treatment with ANS increased apoptosis in cerulein-infused animals. When BN52021 was added, apoptosis was abolished. The measurement of PAF in pancreatic tissue showed a ninefold increase with cerulein treatment alone and a 14-fold increase in cerulein-infused, neutrophil-depleted animals. CONCLUSIONS: The results indicate that cerulein stimulates pancreatic production of PAF. PAF mediates both apoptosis and neutrophil chemotaxis in the pancreas. Neutrophils in turn may convert acinar cells undergoing apoptosis into necrotic cells.


Subject(s)
Diterpenes , Neutrophils/physiology , Pancreatitis/etiology , Platelet Activating Factor/physiology , Acute Disease , Amylases/metabolism , Animals , Ceruletide , Ginkgolides , Lactones/pharmacology , Lipase/metabolism , Male , Pancreatitis/metabolism , Pancreatitis/pathology , Rats , Rats, Sprague-Dawley
8.
Pharmacol Res ; 34(3-4): 171-9, 1996.
Article in English | MEDLINE | ID: mdl-9051712

ABSTRACT

The effect of the lipidosterolic extract of Serenoa repens (LSESR) on experimental prostate enlargement was investigated in three groups of rats: shams treated with LSESR (sham rats), castrated animals treated with estradiol and testosterone (castrated rats), castrated animals treated with estradiol/testosterone and treated with LSESR (castrated and treated rats). Following three months of continuous hormonal treatment, the weight of prostates in estradiol/testosterone-treated castrated rats was significantly increased in comparison with sham-operated rats. Such an increase started rapidly, reached a maximum by 30 days and remained at a plateau or slightly declined thereafter. The increase of prostate total weight induced by the hormone treatment was inhibited by administration of LSESR. Indeed, the weight was significantly lower at day 60 and day 90 for the dorsal and lateral regions of the prostate. The weight of the ventral region of the prostate was significantly lower after 30 and 60 days treatment with LSESR. These results demonstrate that administering LSESR to hormone-treated castrated rats inhibits the increase in prostate wet weight. This effect of LSESR may explain the beneficial effect of this extract in human benign prostatic hypertrophy.


Subject(s)
Androgen Antagonists/therapeutic use , Estradiol , Plant Extracts/therapeutic use , Plants, Medicinal/chemistry , Prostatic Hyperplasia/drug therapy , Testosterone , Animals , Male , Orchiectomy , Organ Size/drug effects , Prostatic Hyperplasia/chemically induced , Prostatic Hyperplasia/pathology , Rats , Rats, Wistar , Serenoa
9.
Nucl Med Biol ; 23(3): 309-14, 1996 Apr.
Article in English | MEDLINE | ID: mdl-8782242

ABSTRACT

As a preliminary study to image platelet-activating factor (PAF) receptors in vivo, comparative study of biodistribution between 1-O-hexadecy1-2-O-N, N-dimethylcarbamoyl-sn-glycero-3-phosphocholine [choline-methyl-11C](L-[11C]dimethylcarbamoyl-PAF) and nonspecific PAF analog, 3-O-hexadecyl-2-O-N,N-dimethylcarbamoyl-sn-glycero-1-phosphocholine [choline-methyl-11C](D-[11C]-dimethylcarbamoyl-PAF) was carried out in both normal and tumor-bearing mice. Higher accumulation of L-[11C]dimethylcarbamoyl-PAF than D-[11C]dimethylcarbamoyl-PAF was observed in normal mice spleen. The co-administration of PAF antagonists dose-dependently reduced the radioactivity level of the L-isomer only in the spleen. In mice bearing Ehrlich tumors and Sarcoma 180, more L-than the D-[11C]-isomer was accumulated in the tumor and spleen. We found that specific accumulation sites for L-[11C]dimethylcarbamoyl-PAF exist in the spleen and tumors than in other tissues. Moreover, the comparison of accumulation between L- and D-[11C] dimethylcarbamoyl-PAF would be a useful procedure for estimation of PAF receptors in vivo.


Subject(s)
Carbon Radioisotopes , Platelet Activating Factor/analogs & derivatives , Platelet Membrane Glycoproteins/analysis , Receptors, Cell Surface , Receptors, G-Protein-Coupled , Sarcoma 180/metabolism , Animals , Kinetics , Male , Mice , Mice, Inbred Strains , Platelet Activating Factor/chemical synthesis , Platelet Activating Factor/pharmacokinetics , Platelet Membrane Glycoproteins/metabolism , Reference Values , Stereoisomerism , Tissue Distribution
10.
Nephrol Dial Transplant ; 11(3): 507-13, 1996 Mar.
Article in English | MEDLINE | ID: mdl-8671822

ABSTRACT

BACKGROUND: Cyclosporin (CsA) is a potent immunosuppressive drug whose main side-effect is nephrotoxicity. In the kidney, CsA induces vasoconstriction with a decrease in renal blood flow (RBF) and glomerular filtration rate (GFR) and a significant increase in renal vascular resistance (RVR). CsA enhances platelet-activating factor (PAF) synthesis in mesangial cells in vitro. PAF, a secondary mediator of anaphylaxis and inflammation, exhibits vasoactive properties in the kidney similar to those of CsA. METHODS: The in situ autoperfused rat kidney model was used to investigate whether PAF plays a role in the haemodynamic injury induced by CsA. RESULTS: In this model, CsA (40 mg/kg and 20 mg/kg i.v.) induced a significant decrease in RBF and in GFR and an increase in RVR. BN 52021, a potent and specific PAF antagonist (20 mg/kg i.v. bolus dose) induced a significant increase in GFR (137 +/- 32% of initial value, P < 0.05). BN 52021 (20 and 10 mg/kg) also significantly prevented the decline in RBF and GFR induced by CsA. CONCLUSIONS: We have demonstrated that the PAF antagonist BN 52021 can minimize the alteration of renal function induced by CsA.


Subject(s)
Cyclosporine/toxicity , Diterpenes , Immunosuppressive Agents/toxicity , Kidney/drug effects , Lactones/pharmacology , Plant Extracts/pharmacology , Platelet Activating Factor/antagonists & inhibitors , Animals , Cyclosporine/administration & dosage , Drug Administration Routes , Ginkgolides , Glomerular Filtration Rate/drug effects , Hemodynamics/drug effects , Immunosuppressive Agents/administration & dosage , Kidney/blood supply , Kidney/physiopathology , Male , Perfusion , Polyethylene Glycols/administration & dosage , Polyethylene Glycols/toxicity , Random Allocation , Rats , Rats, Sprague-Dawley , Renal Circulation/drug effects , Vasoconstriction/drug effects
11.
J Interferon Cytokine Res ; 16(3): 251-7, 1996 Mar.
Article in English | MEDLINE | ID: mdl-8697148

ABSTRACT

The synthetic polyribonucleotide poly(A).poly(U) induces 2',5'-oligoadenylate synthetase activity in the murine macrophage cell line J774A1. The possible role of several cytokines involved in macrophage activation (i.e., IL-1, IL-6, TNF, and IFN) was examined in the present study. It was first demonstrated that among the anticytokine antibodies, only monoclonal antibodies directed against IL-6 inhibited the induction of 2',5'-oligoadenylate synthetase by poly(A).poly(U) in a dose-dependent manner. Moreover, it was established that poly(A).poly(U) elicited IL-6 production in J774A1 cells in a time-and dose-dependent manner. Consequently, the effect of IL-6 on 2',5'-oligoadenylate synthetase activity was studied. IL-6 either alone or in combination with IL-1 and TNF did not induce 2',5'-oligoadenylate synthetase activity. IL-6 did not potentiate IFN-gamma-induced 2'-5'-oligoadenylate synthetase activity. In contrast, addition of IL-6 to the incubation medium potentiated the stimulation of 2'-5'-oligoadenylate synthetase activity by IFN-alpha. These results suggest that IL-6 is a necessary but not sufficient factor in the induction of 2'-5'-oligoadenylate synthetase activity in the J774A1 cell line by poly(A).poly(U).


Subject(s)
2',5'-Oligoadenylate Synthetase/biosynthesis , Interferon Inducers/pharmacology , Interferon-alpha/physiology , Interleukin-6/physiology , Macrophages/drug effects , Poly A-U/pharmacology , Animals , Antibodies/blood , Interferon-alpha/immunology , Interleukin-1/immunology , Interleukin-1/physiology , Interleukin-6/immunology , Macrophages/metabolism , Mice , Tumor Cells, Cultured , Tumor Necrosis Factor-alpha/immunology , Tumor Necrosis Factor-alpha/physiology
12.
Cell Immunol ; 167(2): 205-15, 1996 Feb 01.
Article in English | MEDLINE | ID: mdl-8603429

ABSTRACT

Mouse bone marrow cells cultured for 6 days in the presence of recombinant murine IL-3 and granulocyte-macrophage colony-stimulating factor (GM-CSF) were used as a source of precursors responsive to eosinopoietins. They were further cultured for 7 days in the presence of either a combination of recombinant cytokines or supernatants of bone marrow-derived mast cells (BMMC) activated with either immunological or nonimmunological stimuli. Cytosmears of collected cells were analyzed for eosinophil contents and allowed to demonstrate that supernatants of passively sensitized BMMC support both total cell proliferation and eosinophil production, after various periods of incubation with monoclonal rat anti-mouse IgE antibodies (the 6HD5 mAbs). In contrast, a stimulation with 100 ng/ml dinitrophenylated bovine serum albumin (DNP-BSA) did not generate supernatants displaying such bioactivities. Low doses of methyl ester of L (but not D)-leucine or of the calcium ionophore A23187 also allowed the release of eosinopoietic bioactivities. In addition, immunoreactive IL-5, GM-CSF, and IL-3 were quantified in the BMMC supernatants. These results demonstrate that activated BMMC are able to effect eosinophil production.


Subject(s)
Eosinophils/cytology , Granulocyte-Macrophage Colony-Stimulating Factor/physiology , Interleukin-3/physiology , Interleukin-5/physiology , Mast Cells/immunology , Animals , Bone Marrow Cells , Cell Division , Cells, Cultured , Eosinophils/immunology , Hematopoiesis , Hematopoietic Stem Cells/cytology , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Recombinant Proteins , Time Factors
13.
Anal Chem ; 68(15): 2598-604, 1996 Aug 01.
Article in English | MEDLINE | ID: mdl-21619206

ABSTRACT

The thermodynamic ionization constants (pK(a)(1), pK(a)(2), and pK(a)(3)) of ginkgolide B (9H-1,7a-(epoxymethano)-1H,6aH-cyclopenta[c]furo[2,3-b]furo-[3',2':3,4]cyclopenta[1,2-d]furan-5,9,12-(4H)-trione, 3-tert-butylhexahydro-4,7b,11-trihydroxy-8-methyl-) in aqueous solution have been settled by pH-metric and NMR studies. The three macroscopic pK(a) values as well as the water solubility and the water/n-octanol partition coefficient have been extracted from pH-metric data by means of a nonlinear regression methodology. NMR spectroscopy provided confirmation of the values of the macroscopic constants, information about the effective ionization pathways, and an estimation of the proportions of the various forms under physiologically relevant conditions.

14.
Kidney Int ; 48(2): 337-43, 1995 Aug.
Article in English | MEDLINE | ID: mdl-7564100

ABSTRACT

Platelet activating factor (PAF) is a potent lipid mediator with a broad range of biologic activities. Experimental evidence suggests that PAF plays a role in the pathogenesis of a variety of inflammatory processes including allograft rejection. In this study, we evaluated the effects of the PAF antagonist BN52021 on the course of renal allograft rejection in a rat model. Kidneys from ACI (RT1a) rats were transplanted into fully allogeneic PVG (RT1c) rat recipients. Animals received 60 mg/kg/day of the PAF antagonist or vehicle beginning immediately prior to the transplantation procedure. In rats treated with the PAF antagonist, allograft GFR and plasma flow were maintained at levels that were significantly greater than controls. Despite the improvement in renal allograft function, BN52021 had no effect on allograft histomorphology and both groups manifested intense inflammatory cell infiltration consistent with acute cellular rejection. PAF antagonism reduced urinary excretion of thromboxane metabolites and decreased thromboxane production by homogenates prepared from kidney allografts. The PAF antagonist had no effect on urinary excretion of peptidoleukotriene metabolites or on the production of LTB4 by allografts. These data support a role for PAF in the pathophysiology of acute renal allograft rejection, and they suggest that the hemodynamic effects of PAF during rejection may be mediated through stimulation of thromboxane A2. In view of the beneficial effects of PAF blockade in rejection as well as recent reports describing efficacy in models of cyclosporine nephrotoxicity, PAF antagonists may have clinical applications in human renal allograft recipients.


Subject(s)
Diterpenes , Graft Rejection/physiopathology , Kidney Transplantation , Platelet Activating Factor/physiology , Animals , Ginkgolides , Glomerular Filtration Rate/drug effects , Kidney/drug effects , Kidney/metabolism , Kidney/pathology , Lactones/pharmacology , Leukotriene E4/urine , Male , Plant Extracts/pharmacology , Platelet Activating Factor/antagonists & inhibitors , Rats , Rats, Inbred ACI , Rats, Inbred Strains , Renal Circulation/drug effects , Thromboxane B2/biosynthesis
15.
Am J Physiol ; 268(6 Pt 1): G889-94, 1995 Jun.
Article in English | MEDLINE | ID: mdl-7611410

ABSTRACT

We examined the effect of platelet-activating factor (PAF) on gastric acid secretion by isolated rabbit gastric glands as determined by [14C]aminopyrine ([14C]AP) uptake. PAF, histamine, and carbachol time- and concentration-dependently stimulated [14C]AP uptake, with estimated half-maximal effective concentrations of 60 pM, 0.25 microM, and 0.1 microM, respectively. PAF-induced [14C]AP uptake was inhibited by the specific PAF antagonists BN-50727 and SR-27417 and by the proton pump inhibitors omeprazole and lansoprazole. However, the H2-receptor antagonist famotidine had no effect. Buffering extracellular Ca2+ by ethylene glycol-bis(beta-amino-ethyl ether)-N,N,N',N'-tetraacetic acid resulted in a shift to the right of the time-course effect of PAF without altering the maximal response, whereas buffering intracellular Ca2+ by 1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid 2-acetoxymethyl ester, as well as blocking Ca2+ channels by verapamil, inhibited PAF-induced [14C]AP uptake. Intracellular Ca2+ concentration in isolated rabbit gastric glands, as measured by fura 2-acetoxymethyl ester, concentration-dependently increased in response to PAF, to a maximum of 1.5-fold for 0.1 microM. These results suggest that PAF stimulates gastric acid secretion via specific receptors activating intracellular Ca2+ mobilization, which could be located on the parietal cells.


Subject(s)
Gastric Acid/metabolism , Gastric Mucosa/drug effects , Platelet Activating Factor/pharmacology , Aminopyrine/metabolism , Animals , Azepines/pharmacology , Biological Transport/drug effects , Calcium/metabolism , Carbachol/pharmacology , Dose-Response Relationship, Drug , Egtazic Acid/analogs & derivatives , Egtazic Acid/pharmacology , Famotidine/pharmacology , Fluorescent Dyes , Gastric Mucosa/metabolism , Histamine/pharmacology , In Vitro Techniques , Kinetics , Male , Platelet Activating Factor/antagonists & inhibitors , Rabbits , Thiazoles/pharmacology , Thienopyridines , Triazoles/pharmacology , Verapamil/pharmacology
16.
Int Arch Allergy Immunol ; 107(1-3): 272-4, 1995.
Article in English | MEDLINE | ID: mdl-7542078

ABSTRACT

The effects of two monocyclic monoterpenes, limonene and sobrerol, known as inhibitors of farnesyltransferase activity, were studied on monocrotaline (MCT)-induced lung injury, pulmonary hypertension and right ventricular hypertrophy in male Wistar rats. After 14 days, pulmonary arterial pressure values and the right ventricle to left ventricle plus septum weight ratios, RV/(LV + S), were markedly increased in rats subcutaneously injected with MCT (60 mg/kg). Limonene and sobrerol, administered daily at the oral dose of 400 mg/rat, markedly decreased the MCT-induced alterations. After treatment for 21 days, limonene still prevented pulmonary hypertension and the increase in RV/(LV + S). Both monoterpenes also reduced the increase in pulmonary arterial media thickness, the development of interstitial fibrosis and the increase in the number of macrophages in intra-alveolar spaces and of lymphocytes around the pulmonary veins. The present data indicate that treatment of rats with inhibitors of farnesyltransferase, like limonene and sobrerol, regulate the development of pulmonary hypertension.


Subject(s)
Alkyl and Aryl Transferases , Hypertension, Pulmonary/prevention & control , Lung/blood supply , Monocrotaline/toxicity , Muscle Proteins/metabolism , Neovascularization, Pathologic/prevention & control , Protein Processing, Post-Translational/drug effects , Terpenes/therapeutic use , Transferases/antagonists & inhibitors , Animals , Cyclohexenes , Drug Evaluation, Preclinical , Farnesyltranstransferase , Hypertension, Pulmonary/chemically induced , Hypertension, Pulmonary/physiopathology , Hypertrophy, Right Ventricular/chemically induced , Hypertrophy, Right Ventricular/physiopathology , Hypertrophy, Right Ventricular/prevention & control , Limonene , Lung/drug effects , Lung/pathology , Male , Muscle, Smooth, Vascular/drug effects , Muscle, Smooth, Vascular/pathology , Neovascularization, Pathologic/chemically induced , Protein Prenylation/drug effects , Pulmonary Artery/drug effects , Pulmonary Artery/pathology , Rats , Rats, Sprague-Dawley , Terpenes/pharmacology
17.
Clin Exp Allergy ; 25(4): 304-11, 1995 Apr.
Article in English | MEDLINE | ID: mdl-7600375

ABSTRACT

The present study examined the effect of beta 2-adrenoceptor agonists on the interleukin-4 (IL-4)-driven IgE production and on the possible mechanisms of action of these compounds. We present evidence that salbutamol and fenoterol potentiated the IL-4-induced IgE production by human peripheral blood mononuclear cells (PBMC). No significant effect of incubation in the presence of beta 2-adrenoceptor agonists on IgG, IgA and IgM production was observed. Salbutamol and fenoterol inhibited interferon-(IFN)-gamma production by PHA-activated human PBMC suggesting that the blockade of the production of this cytokine could possibly explain the enhancement of IgE production. Salbutamol and fenoterol potentiated the IL-4-induced production of sCD23 whereas no effect on CD23 expression was observed. The potentiating effect of salbutamol on IgE production was blocked by two antagonists of beta 2-adrenoceptor, namely butoxamine and D,L-propranolol, suggesting a beta-adrenoceptor-mediated event. These results demonstrate that beta 2-adrenoceptor stimulation results in an increase in IgE production by human B lymphocytes.


Subject(s)
Adrenergic beta-Agonists/pharmacology , Immunoglobulin E/biosynthesis , Monocytes/metabolism , Albuterol/pharmacology , Cell Survival/drug effects , Humans , Immunoglobulins/blood , Interleukin-4/pharmacology , Lymphocyte Activation/drug effects , Lymphokines/blood , Receptors, Adrenergic, beta/physiology , Receptors, IgE/metabolism , Solubility
18.
Acta Ophthalmol Scand ; 73(2): 155-7, 1995 Apr.
Article in English | MEDLINE | ID: mdl-7656145

ABSTRACT

The alkaloid vincristine displays considerable toxicity, particularly for the retina. This type of retinopathy being an inflammatory disease, we measured the effects of a new hetrazepine platelet activating factor antagonist, BN 50730, on a vincristine-induced retinopathy in the rat. Retinal impairments were established by recording several parameters of the electroretinogram obtained from isolated retina. Our results indicate that 1) the increase in PIII duration induced by vincristine is significantly reduced by BN 50730 administration 2) the decrease in the amplitude of the PIII/b wave ratio caused by vincristine is partially inhibited by treatment with BN 50730. These experiments suggest that platelet activating factor is implicated in vincristine retinopathy and demonstrate the therapeutic effect of a specific antagonist of the mediator.


Subject(s)
Azepines/pharmacology , Platelet Activating Factor/antagonists & inhibitors , Retina/drug effects , Retinal Diseases/prevention & control , Triazoles/pharmacology , Vincristine/toxicity , Animals , Dark Adaptation , Electroretinography/drug effects , Rats , Rats, Sprague-Dawley , Retina/physiology , Retinal Diseases/chemically induced , Retinal Diseases/physiopathology , Thienopyridines
20.
Ophthalmic Res ; 27(3): 153-7, 1995.
Article in English | MEDLINE | ID: mdl-8538992

ABSTRACT

Platelet-activating factor (PAF) has been shown to alter the trans-retinal potential recorded from light-stimulated isolated retina. In the present study, we investigated the effect of cholera and pertussis toxins on PAF-induced impairment of the electroretinogram (ERG). Administered alone, 2 x 10(-7) M PAF induced a very marked and rapid drop in the b-wave amplitude. When 75 micrograms/l of cholera toxin was coadministered with PAF in the perfusion solution, no b-wave drop was observed, suggesting that the effect of PAF on retinal function was mediated by GTP-binding protein (G protein). Similarly, a low dose of pertussis toxin (5 micrograms/l) was sufficient to antagonize the action of PAF on the ERG. Our results suggest that the irreversible and deleterious effect of PAF on ERG is mediated by a G protein mechanism, located in the neural retina.


Subject(s)
Cholera Toxin/pharmacology , Pertussis Toxin , Platelet Activating Factor/antagonists & inhibitors , Retina/physiology , Virulence Factors, Bordetella/pharmacology , Animals , Drug Combinations , Electroretinography/drug effects , Female , GTP-Binding Proteins/physiology , Light , Platelet Activating Factor/pharmacology , Rats , Rats, Wistar , Retina/drug effects , Signal Transduction
SELECTION OF CITATIONS
SEARCH DETAIL
...